{Reference Type}: Journal Article
{Title}: Treatment options for advanced hepatocellular carcinoma: the potential of biologics.
{Author}: Rossari F;Foti S;Camera S;Persano M;Casadei-Gardini A;Rimini M;
{Journal}: Expert Opin Biol Ther
{Volume}: 24
{Issue}: 6
{Year}: 2024 Jun 24
{Factor}: 5.589
{DOI}: 10.1080/14712598.2024.2363234
{Abstract}: <B>UNASSIGNED: </B>Advanced hepatocellular carcinoma (HCC) represents a significant global health burden, whose treatment has been recently revolutionized by the advent of biologic treatments. Despite that, innovative therapeutic regimens and approaches, especially immune-based, remain to be explored aiming at extending the therapeutic benefits to a wider population of patients.<BR><B>UNASSIGNED: </B>This review comprehensively discusses the evolving landscape of biological treatment modalities for advanced HCC, including immune checkpoint inhibitors, antiangiogenic monoclonal antibodies, tumor-targeting monoclonal antibodies either naked or drug-conjugated, therapeutic vaccines, oncolytic viruses, adoptive cell therapies, and cytokine-based therapies. Key clinical trials and preclinical studies are examined, highlighting the actual or potential impact of these interventions in reshaping treatment paradigms for HCC.<BR><B>UNASSIGNED: </B>Tailored and rational combination strategies, leveraging the synergistic effects of different modalities, represent a promising approach to maximize treatment efficacy in advanced HCC, which should aim at conversion endpoints to increase the fraction of patients eligible for curative approaches. The identification of predictive biomarkers holds the key to optimizing patient selection and improving therapeutic outcomes.